GC Cell Publishes Glioblastoma CIK Study
Academic evidence has been established for the utilization of Cytokine-Induced Killer (CIK) cells in the treatment of glioblastoma (GBM), a representative malignant brain tumor occurring in adults. GC Cell announced on Oct. 1 that the results of its CIK cell-based glioblastoma research were publishe
Academic research confirms the use of Cytokine-Induced Killer (CIK) cells in treating glioblastoma (GBM), a lethal brain tumor affecting adults. GC Cell revealed on October 1st that its CIK cell-based glioblastoma study was published in the international journal Frontiers in Neurology. This translational research examined the characterization of patient-derived CIK cells, non-clinical research, and real patient treatment data from multiple perspectives.
The research team retrospectively reviewed the medical records of 12 patients with recurrent glioblastoma treated with autologous CIK cell therapy, alongside temozolomide, bevacizumab, or nivolumab. The analysis revealed a median progression-free survival of 10.5 months and a median overall survival of 14.2 months for the entire patient group.
Treatment safety was confirmed, with no instances of treatment discontinuation due to adverse reactions related to CIK cell therapy, nor severe allergic reactions, cytokine release syndrome (CRS), or treatment-related fatalities. However, due to the retrospective exploratory nature of the study and its small sample size, the observed survival period is anticipated to serve as evidence for future research instead of being considered a direct result of the cell therapy.
Glioblastoma, characterized by frequent recurrence and limited treatment options even after standard therapy, poses a significant challenge. Choi Jong-kwon, a professor at Konyang University Hospital's Department of Hematology and Oncology and the study's corresponding author, noted the significance of exploring CIK cell therapy's clinical applicability in cancer types where immunotherapy is not easily applicable.
Won Sung-yong, GC Cell's CEO, stressed the company's commitment to accumulating evidence to verify the potential of cell therapy in cancer types with high unmet medical needs and expanding cooperation with both domestic and foreign researchers.
Written by urgent.news from BusinessKorea's reporting — not their text. Machine-written — may contain errors; check the original before relying on it.
